Huntington's Disease — Research Summary
Printed from RareWays (rareways.com.au) on 25 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
MMP9 as a shared immune-related gene in Alzheimer's and Huntington's diseases: a cross-tissue transcriptomic analysis.
Li Xuepan et al. — Artificial cells, nanomedicine, and biotechnology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42030987/
- 2.
Sleep in Huntington's disease gene expansion carriers: A systematic review.
Sassi Karina Lucia Moreira et al. — Sleep medicine (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42150232/
- 3.
Unexpected mechanisms of repurposed drugs in the pathogenic pathways of neurodegenerative diseases. Discovering new neuroprotective therapies in cellular models.
Arasmou-Idrovo M S et al. — Neuropharmacology (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42061810/
- 4.
Dysregulation of arginase and arginine pathways in neurodegenerative diseases: Metabolic and cellular dysfunction and therapeutic implications.
Nalepa Martyna et al. — Free radical biology & medicine (16 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42156213/
- 5.
ROS-HIF1α-driven glycolytic reprogramming sustains ATP production in Huntington's disease.
Wu Ching-Wen et al. — Neurobiology of disease (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42190991/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease
Recruiting — Phase 1 — Hoffmann-La Roche
https://clinicaltrials.gov/study/NCT07246941
- 2.
Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers
Recruiting — Hoffmann-La Roche
https://clinicaltrials.gov/study/NCT06667414
- 3.
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Recruiting — CHDI Foundation, Inc.
https://clinicaltrials.gov/study/NCT01574053
- 4.
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
Recruiting — Phase 2 — Western Sydney Local Health District
https://clinicaltrials.gov/study/NCT05509153
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Huntington's Disease
Huntington's disease is a genetic condition that causes the gradual breakdown of nerve cells in the brain. It affects movement, thinking, and behaviour. Symptoms usually begin in mid-adulthood. There is currently no cure, but research into treatments is very active.
Most Recent Research
Alzheimer's disease (AD) and Huntington's disease (HD) share neuroinflammatory mechanisms, yet their specific immune microenvironments remain poorly understood. Integrating transcriptomic profiles of peripheral blood and frontal cortex tissues with 2,160 immune-related genes, we analysed their shared immunopathology. Differential analysis identified 64 peripheral and 159 central consistently dysregulated immune genes, intersecting to isolate 10 co-expressed all-immune genes. Functional enrichment highlighted neutrophil and monocyte activation, alongside IL-17 and T-cell receptor signalling pathways. Machine learning (LASSO and Boruta) robustly pinpointed MMP9 as the core shared immune hub gene. External validation revealed MMP9 exhibited modest diagnostic performance in peripheral blood (AD AUC = 0.616; HD AUC = 0.619) but stronger predictive accuracy in brain tissues (AD AUC = 0.825; HD AUC = 0.876). Furthermore, MMP9 expression positively correlated with neutrophil and M0 macrophage infiltration. While modest peripheral accuracy limits its standalone diagnostic utility, this cross-tissue analysis establishes MMP9 as a consistently upregulated candidate molecular indicator of shared neuroinflammation, offering a valuable target for future mechanistic research.
Common Questions
What is Huntington's Disease?
Huntington's disease is a genetic condition that causes the gradual breakdown of nerve cells in the brain. It affects movement, thinking, and behaviour. Symptoms usually begin in mid-adulthood. There is currently no cure, but research into treatments is very active.
How many clinical trials are available for Huntington's Disease?
RareWays currently indexes 232 clinical trials for Huntington's Disease, of which 45 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Huntington's Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Huntington's Disease.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.